Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Ptc Therapeutics (PTCT) over the last 14 years, with Q3 2025 value amounting to -$69.7 million.

  • Ptc Therapeutics' Free Cash Flow rose 1002.14% to -$69.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $705.2 million, marking a year-over-year increase of 47859.06%. This contributed to the annual value of -$114.2 million for FY2024, which is 3888.88% up from last year.
  • Ptc Therapeutics' Free Cash Flow amounted to -$69.7 million in Q3 2025, which was up 1002.14% from -$59.6 million recorded in Q2 2025.
  • Ptc Therapeutics' 5-year Free Cash Flow high stood at $868.4 million for Q1 2025, and its period low was -$174.6 million during Q4 2022.
  • Moreover, its 5-year median value for Free Cash Flow was -$59.6 million (2025), whereas its average is -$12.1 million.
  • In the last 5 years, Ptc Therapeutics' Free Cash Flow crashed by 34424.65% in 2021 and then skyrocketed by 131954.62% in 2025.
  • Ptc Therapeutics' Free Cash Flow (Quarter) stood at -$77.6 million in 2021, then tumbled by 125.08% to -$174.6 million in 2022, then skyrocketed by 39.37% to -$105.9 million in 2023, then soared by 68.1% to -$33.8 million in 2024, then tumbled by 106.53% to -$69.7 million in 2025.
  • Its last three reported values are -$69.7 million in Q3 2025, -$59.6 million for Q2 2025, and $868.4 million during Q1 2025.